Portfolio Holdings Detail for ISIN IE00BYZK4776
Stock Name / Fund iShares Healthcare Innovation UCITS ETF USD (Acc)
Issuer Blackrock
Entity holding fund iShares IV Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF Ticker DRDR(GBX) LSE
ETF Ticker 2B78(EUR) F
ETF Ticker 2B78.DE(EUR) CXE
ETF Ticker DRDR.LS(GBX) CXE
ETF Ticker HEAL.AS(EUR) CXE
ETF Ticker HEAL.LS(USD) CXE
ETF Ticker HEALz(USD) CXE
ETF Ticker HEAL(EUR) ETF Plus
ETF Ticker DRDR.L(GBP) LSE

Holdings detail for ANAB

Stock Name	AnaptysBio Inc
Ticker	ANAB(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US0327241065
LEI	529900HH4WQT03IG1A12

Show aggregate ANAB holdings

News associated with ANAB

AnaptysBio (NASDAQ:ANAB) Receives “Outperform” Rating from Wedbush: AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a report released on Tuesday,RTT News reports. They presently have a $45.00 price target on the biotechnology company’s stock. Wedbush’s price objective points to a potential upside of 127.16% from the company’s current price. Several other […] - 2025-09-18 02:24:44
Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) Price Target at $46.13: Shares of AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy […] - 2025-09-16 02:46:48
AnaptysBio, Inc. (NASDAQ:ANAB) Receives $46.13 Average Target Price from Analysts: Shares of AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) have earned an average rating of “Moderate Buy” from the ten analysts that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to […] - 2025-08-22 03:12:54
AnaptysBio (NASDAQ:ANAB) Receives Neutral Rating from UBS Group: UBS Group restated their neutral rating on shares of AnaptysBio (NASDAQ:ANAB – Free Report) in a research report report published on Tuesday morning, Marketbeat Ratings reports. The brokerage currently has a $20.00 price target on the biotechnology company’s stock, up from their prior price target of $18.00. A number of other research analysts have also […] - 2025-08-13 04:26:45
Zurcher Kantonalbank Zurich Cantonalbank Sells 660 Shares of AnaptysBio, Inc. (NASDAQ:ANAB): Zurcher Kantonalbank Zurich Cantonalbank trimmed its position in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 24.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,062 shares of the biotechnology company’s stock after selling 660 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in […] - 2025-08-11 05:32:56
Federated Hermes Inc. Has $154,000 Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB): Federated Hermes Inc. lowered its stake in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 81.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 8,274 shares of the biotechnology company’s stock after selling 36,910 shares during the quarter. Federated Hermes Inc.’s holdings […] - 2025-08-11 04:48:58
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of “Moderate Buy” from Analysts: AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The […] - 2025-07-30 04:24:54
Alps Advisors Inc. Lowers Holdings in AnaptysBio, Inc. (NASDAQ:ANAB): Alps Advisors Inc. trimmed its holdings in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 6.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,126 shares of the biotechnology company’s stock after selling 1,478 shares during the period. Alps Advisors Inc. owned […] - 2025-07-15 06:26:00
Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $42.38: AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the […] - 2025-07-03 02:41:00
AnaptysBio (NASDAQ:ANAB) Upgraded at HC Wainwright: AnaptysBio (NASDAQ:ANAB – Get Free Report) was upgraded by research analysts at HC Wainwright from a “neutral” rating to a “buy” rating in a note issued to investors on Wednesday, MarketBeat.com reports. The firm currently has a $38.00 price objective on the biotechnology company’s stock, up from their previous price objective of $22.00. HC Wainwright’s […] - 2025-06-06 02:58:51
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Acquired by Squarepoint Ops LLC: Squarepoint Ops LLC raised its stake in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 81.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 80,870 shares of the biotechnology company’s stock after purchasing an additional 36,365 shares during the period. Squarepoint Ops LLC’s holdings in AnaptysBio were worth $1,071,000 as of its most recent filing […] - 2025-06-01 05:29:02
AnaptysBio (NASDAQ:ANAB) Earns Buy Rating from Guggenheim: AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a note issued to investors on Wednesday, MarketBeat Ratings reports. They presently have a $90.00 target price on the biotechnology company’s stock, up from their previous target price of $54.00. Guggenheim’s price objective points to a […] - 2025-05-30 03:08:51
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Analyst Upgrade: AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report)’s share price gapped up prior to trading on Wednesday after Guggenheim raised their price target on the stock from $52.00 to $54.00. The stock had previously closed at $20.13, but opened at $21.14. Guggenheim currently has a buy rating on the stock. AnaptysBio shares last traded at $22.10, […] - 2025-05-30 02:27:21
D. E. Shaw & Co. Inc. Reduces Stake in AnaptysBio, Inc. (NASDAQ:ANAB): D. E. Shaw & Co. Inc. trimmed its stake in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 12.1% during the fourth quarter, Holdings Channel reports. The fund owned 197,107 shares of the biotechnology company’s stock after selling 27,030 shares during the period. D. E. Shaw & Co. Inc.’s holdings in AnaptysBio were worth $2,610,000 as […] - 2025-05-20 04:57:05
18,954 Shares in AnaptysBio, Inc. (NASDAQ:ANAB) Bought by Graham Capital Management L.P.: Graham Capital Management L.P. bought a new position in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) in the 4th quarter, Holdings Channel.com reports. The firm bought 18,954 shares of the biotechnology company’s stock, valued at approximately $251,000. Other hedge funds also recently made changes to their positions in the company. Tower Research Capital LLC TRC increased […] - 2025-05-19 05:26:52
Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $35.88: AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to […] - 2025-05-14 02:34:53
Barclays PLC Boosts Stake in AnaptysBio, Inc. (NASDAQ:ANAB): Barclays PLC boosted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 88.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 83,567 shares of the biotechnology company’s stock after acquiring an additional 39,267 shares during the […] - 2025-05-05 05:26:54
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Federated Hermes Inc.: Federated Hermes Inc. lessened its holdings in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 85.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,184 shares of the biotechnology company’s stock after selling 272,059 shares during the quarter. Federated […] - 2025-04-17 05:18:48
AnaptysBio, Inc. (NASDAQ:ANAB) Stock Holdings Increased by Vanguard Group Inc.: Vanguard Group Inc. lifted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 8.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,843,740 shares of the biotechnology company’s stock after purchasing an additional 143,584 shares during the quarter. Vanguard Group Inc. owned approximately 0.06% of AnaptysBio worth $24,411,000 as […] - 2025-04-16 04:22:49
Reviewing AnaptysBio (NASDAQ:ANAB) and Silo Pharma (NASDAQ:SILO): AnaptysBio (NASDAQ:ANAB – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk. Risk & Volatility AnaptysBio has a beta of […] - 2025-03-25 03:56:46
Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $35.11: AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eleven analysts that are currently covering the company, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the […] - 2025-03-25 03:52:42
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $42.00 at JPMorgan Chase & Co.: AnaptysBio (NASDAQ:ANAB – Get Free Report) had its price objective increased by JPMorgan Chase & Co. from $36.00 to $42.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 156.10% from the […] - 2025-03-07 04:10:52
AnaptysBio (NASDAQ:ANAB) Given Neutral Rating at HC Wainwright: AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “neutral” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $22.00 price target on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 31.34% from the company’s previous close. Several […] - 2025-03-06 06:31:49
Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) PT at $36.20: AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the eleven research firms that are currently covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation […] - 2025-02-28 04:26:55
Jennison Associates LLC Boosts Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB): Jennison Associates LLC boosted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 1.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 269,131 shares of the biotechnology company’s stock after acquiring an additional 4,242 shares during the […] - 2025-02-07 07:55:30
Wedbush Predicts AnaptysBio’s Q1 Earnings (NASDAQ:ANAB): AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) – Equities research analysts at Wedbush lifted their Q1 2025 earnings estimates for AnaptysBio in a research note issued on Monday, February 3rd. Wedbush analyst D. Nierengarten now expects that the biotechnology company will earn ($0.44) per share for the quarter, up from their previous estimate of ($0.96). Wedbush […] - 2025-02-06 04:36:55
Wolfe Research Initiates Coverage on AnaptysBio (NASDAQ:ANAB): Wolfe Research assumed coverage on shares of AnaptysBio (NASDAQ:ANAB – Free Report) in a research report sent to investors on Tuesday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $25.00 target price on the biotechnology company’s stock. Several other research firms also recently commented on ANAB. Guggenheim cut their target price on […] - 2025-02-05 07:10:52

iShares Healthcare Innovation UCITS ETF USD (Acc) ANAB holdings

Date	Number of ANAB Shares Held	Base Market Value of ANAB Shares	Local Market Value of ANAB Shares	Change in ANAB Base Value	Current Price per ANAB Share Held	Previous Price per ANAB Share Held
2025-11-11 (Tuesday)	26,447	USD 887,561	USD 887,561	USD -11,108	USD 33.56	USD 33.98
2025-11-10 (Monday)	26,447	USD 898,669	USD 898,669	USD -149,955	USD 33.98	USD 39.65
2025-11-07 (Friday)	26,447	USD 1,048,624	USD 1,048,624	USD 38,349	USD 39.65	USD 38.2
2025-11-06 (Thursday)	26,447	USD 1,010,275	USD 1,010,275	USD 58,183	USD 38.2	USD 36
2025-11-05 (Wednesday)	26,447	USD 952,092	USD 952,092	USD 33,323	USD 36	USD 34.74
2025-11-04 (Tuesday)	26,447	USD 918,769	USD 918,769	USD -34,381	USD 34.74	USD 36.04
2025-11-03 (Monday)	26,447	USD 953,150	USD 953,150	USD -14,281	USD 36.04	USD 36.58
2025-10-31 (Friday)	26,447	USD 967,431	USD 967,431	USD 2,909	USD 36.58	USD 36.47
2025-10-30 (Thursday)	26,447	USD 964,522	USD 964,522	USD 9,256	USD 36.47	USD 36.12
2025-10-29 (Wednesday)	26,447	USD 955,266	USD 955,266	USD -1,058	USD 36.12	USD 36.16
2025-10-28 (Tuesday)	26,447	USD 956,324	USD 956,324	USD -528	USD 36.16	USD 36.18
2025-10-27 (Monday)	26,447	USD 956,852	USD 956,852	USD 29,356	USD 36.18	USD 35.07

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ANAB by Blackrock for IE00BYZK4776

Show aggregate share trades of ANAB

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-10-24 SELL -226 35.070 35.145 35.138 USD -7,941 21.80 Loss of -3,013 on sale
2025-09-11 BUY 115 23.200 23.635 23.592 USD 2,713 20.92
2025-07-08 SELL -113 24.250 24.730 24.682 USD -2,789 20.59 Loss of -463 on sale
2025-06-24 SELL -116 23.320 23.800 23.752 USD -2,755 20.41 Loss of -387 on sale
2025-06-23 SELL -116 22.820 23.935 23.823 USD -2,764 20.40 Loss of -398 on sale
2025-06-20 BUY 6,007 23.170 23.450 23.422 USD 140,696 20.37
2025-06-11 SELL -90 23.600 24.370 24.293 USD -2,186 20.20 Loss of -368 on sale
2025-05-30 SELL -90 22.230 22.590 22.554 USD -2,030 20.05 Loss of -226 on sale
2025-05-21 BUY 90 20.805 21.310 21.259 USD 1,913 20.00
2025-05-14 SELL -540 19.450 20.755 20.624 USD -11,137 19.98 Loss of -346 on sale
2025-04-30 SELL -89 22.220 22.515 22.485 USD -2,001 19.93 Loss of -228 on sale
2025-04-28 SELL -89 21.330 21.420 21.411 USD -1,906 19.90 Loss of -134 on sale
2025-04-25 SELL -89 20.700 21.135 21.092 USD -1,877 19.89 Loss of -107 on sale
2025-04-11 SELL -564 17.170 17.310 17.296 USD -9,755 19.91 Profit of 1,472 on sale
2025-04-08 SELL -276 16.980 18.694 18.523 USD -5,112 20.02 Profit of 412 on sale
2025-04-07 SELL -192 17.780 18.740 18.644 USD -3,580 20.04 Profit of 269 on sale
2025-03-31 SELL -184 18.590 18.805 18.784 USD -3,456 20.11 Profit of 245 on sale
2025-03-21 SELL -182 17.080 18.210 18.097 USD -3,294 20.25 Profit of 392 on sale
2025-03-12 SELL -95 17.710 18.500 18.421 USD -1,750 20.60 Profit of 207 on sale
2025-02-28 SELL -95 16.820 19.450 19.187 USD -1,823 21.16 Profit of 187 on sale
2025-02-25 BUY 95 17.190 17.600 17.559 USD 1,668 21.38
2025-02-20 SELL -94 18.870 19.730 19.644 USD -1,847 21.56 Profit of 180 on sale
2025-02-19 BUY 186 19.610 20.500 20.411 USD 3,796 21.59
2025-02-18 BUY 93 19.780 21.570 21.391 USD 1,989 21.63
2024-12-30 SELL -183 13.220 13.340 13.328 USD -2,439 24.69 Profit of 2,079 on sale
2024-12-06 SELL -88 24.810 24.950 24.936 USD -2,194 24.80 Loss of -12 on sale
2024-12-04 SELL -88 24.080 24.700 24.638 USD -2,168 24.86 Profit of 20 on sale
2024-12-03 SELL -176 22.000 25.160 24.844 USD -4,373 24.97 Profit of 22 on sale
2024-11-21 SELL -93 21.170 21.640 21.593 USD -2,008 25.36 Profit of 350 on sale
2024-11-20 SELL -96 20.310 20.590 20.562 USD -1,974 25.64 Profit of 487 on sale
2024-11-19 SELL -96 19.970 20.070 20.060 USD -1,926 25.97 Profit of 567 on sale
2024-11-18 SELL -360 18.880 19.240 19.204 USD -6,913 26.41 Profit of 2,596 on sale
2024-11-12 SELL -90 21.500 22.805 22.675 USD -2,041 26.74 Profit of 366 on sale
2024-11-07 SELL -90 21.490 22.620 22.507 USD -2,026 27.56 Profit of 455 on sale
2024-11-05 SELL -180 19.880 19.930 19.925 USD -3,587 28.75 Profit of 1,588 on sale
2024-10-28 SELL -89 30.490 32.420 32.227 USD -2,868 33.90 Profit of 149 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-10-24	SELL	-226	35.070	35.145	35.138	USD -7,941	21.80 Loss of -3,013 on sale
2025-09-11	BUY	115	23.200	23.635	23.592	USD 2,713	20.92
2025-07-08	SELL	-113	24.250	24.730	24.682	USD -2,789	20.59 Loss of -463 on sale
2025-06-24	SELL	-116	23.320	23.800	23.752	USD -2,755	20.41 Loss of -387 on sale
2025-06-23	SELL	-116	22.820	23.935	23.823	USD -2,764	20.40 Loss of -398 on sale
2025-06-20	BUY	6,007	23.170	23.450	23.422	USD 140,696	20.37
2025-06-11	SELL	-90	23.600	24.370	24.293	USD -2,186	20.20 Loss of -368 on sale
2025-05-30	SELL	-90	22.230	22.590	22.554	USD -2,030	20.05 Loss of -226 on sale
2025-05-21	BUY	90	20.805	21.310	21.259	USD 1,913	20.00
2025-05-14	SELL	-540	19.450	20.755	20.624	USD -11,137	19.98 Loss of -346 on sale
2025-04-30	SELL	-89	22.220	22.515	22.485	USD -2,001	19.93 Loss of -228 on sale
2025-04-28	SELL	-89	21.330	21.420	21.411	USD -1,906	19.90 Loss of -134 on sale
2025-04-25	SELL	-89	20.700	21.135	21.092	USD -1,877	19.89 Loss of -107 on sale
2025-04-11	SELL	-564	17.170	17.310	17.296	USD -9,755	19.91 Profit of 1,472 on sale
2025-04-08	SELL	-276	16.980	18.694	18.523	USD -5,112	20.02 Profit of 412 on sale
2025-04-07	SELL	-192	17.780	18.740	18.644	USD -3,580	20.04 Profit of 269 on sale
2025-03-31	SELL	-184	18.590	18.805	18.784	USD -3,456	20.11 Profit of 245 on sale
2025-03-21	SELL	-182	17.080	18.210	18.097	USD -3,294	20.25 Profit of 392 on sale
2025-03-12	SELL	-95	17.710	18.500	18.421	USD -1,750	20.60 Profit of 207 on sale
2025-02-28	SELL	-95	16.820	19.450	19.187	USD -1,823	21.16 Profit of 187 on sale
2025-02-25	BUY	95	17.190	17.600	17.559	USD 1,668	21.38
2025-02-20	SELL	-94	18.870	19.730	19.644	USD -1,847	21.56 Profit of 180 on sale
2025-02-19	BUY	186	19.610	20.500	20.411	USD 3,796	21.59
2025-02-18	BUY	93	19.780	21.570	21.391	USD 1,989	21.63
2024-12-30	SELL	-183	13.220	13.340	13.328	USD -2,439	24.69 Profit of 2,079 on sale
2024-12-06	SELL	-88	24.810	24.950	24.936	USD -2,194	24.80 Loss of -12 on sale
2024-12-04	SELL	-88	24.080	24.700	24.638	USD -2,168	24.86 Profit of 20 on sale
2024-12-03	SELL	-176	22.000	25.160	24.844	USD -4,373	24.97 Profit of 22 on sale
2024-11-21	SELL	-93	21.170	21.640	21.593	USD -2,008	25.36 Profit of 350 on sale
2024-11-20	SELL	-96	20.310	20.590	20.562	USD -1,974	25.64 Profit of 487 on sale
2024-11-19	SELL	-96	19.970	20.070	20.060	USD -1,926	25.97 Profit of 567 on sale
2024-11-18	SELL	-360	18.880	19.240	19.204	USD -6,913	26.41 Profit of 2,596 on sale
2024-11-12	SELL	-90	21.500	22.805	22.675	USD -2,041	26.74 Profit of 366 on sale
2024-11-07	SELL	-90	21.490	22.620	22.507	USD -2,026	27.56 Profit of 455 on sale
2024-11-05	SELL	-180	19.880	19.930	19.925	USD -3,587	28.75 Profit of 1,588 on sale
2024-10-28	SELL	-89	30.490	32.420	32.227	USD -2,868	33.90 Profit of 149 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ANAB

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	92,308	0	183,005	50.4%
2025-09-18	58,201	0	106,687	54.6%
2025-09-17	105,431	873	320,514	32.9%
2025-09-16	191,351	14,369	566,480	33.8%
2025-09-15	166,542	12,680	469,729	35.5%
2025-09-12	122,619	0	188,382	65.1%
2025-09-11	107,589	0	138,671	77.6%
2025-09-10	122,385	0	174,863	70.0%
2025-09-09	69,966	0	98,957	70.7%
2025-09-08	74,734	0	107,417	69.6%
2025-09-05	75,329	0	104,698	71.9%
2025-09-04	113,219	0	168,716	67.1%
2025-09-03	102,133	0	140,378	72.8%
2025-09-02	29,714	122	45,208	65.7%
2025-08-29	105,678	0	137,685	76.8%
2025-08-28	18,607	0	46,589	39.9%
2025-08-27	47,648	870	76,479	62.3%
2025-08-26	48,080	1,000	99,553	48.3%
2025-08-25	35,311	0	52,989	66.6%
2025-08-22	54,262	328	78,722	68.9%
2025-08-21	83,095	2,019	146,968	56.5%
2025-08-20	58,202	0	101,839	57.2%
2025-08-19	69,349	0	109,095	63.6%
2025-08-18	45,757	300	66,872	68.4%
2025-08-15	49,379	0	85,030	58.1%
2025-08-14	51,063	1	93,195	54.8%
2025-08-13	176,608	66	417,787	42.3%
2025-08-12	48,149	0	98,556	48.9%
2025-08-11	70,002	0	155,360	45.1%
2025-08-08	139,058	21,803	613,210	22.7%
2025-08-07	79,784	643	173,811	45.9%
2025-08-06	77,521	3	179,677	43.1%
2025-08-05	65,167	0	161,070	40.5%
2025-08-04	27,989	0	67,303	41.6%
2025-08-01	45,155	0	116,703	38.7%
2025-07-31	84,525	960	201,920	41.9%
2025-07-30	155,697	816	333,900	46.6%
2025-07-29	57,495	60	119,685	48.0%
2025-07-28	59,023	0	119,581	49.4%
2025-07-25	73,692	49	186,893	39.4%
2025-07-24	70,238	54	146,166	48.1%
2025-07-23	92,577	1,556	353,307	26.2%
2025-07-22	55,841	4,032	156,457	35.7%
2025-07-21	102,030	40	188,906	54.0%
2025-07-18	50,078	9	80,374	62.3%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Healthcare Innovation UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares IV Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300ZP07LMR36K1T02
ETF Ticker	DRDR(GBX) LSE
ETF Ticker	2B78(EUR) F
ETF Ticker	2B78.DE(EUR) CXE
ETF Ticker	DRDR.LS(GBX) CXE
ETF Ticker	HEAL.AS(EUR) CXE
ETF Ticker	HEAL.LS(USD) CXE
ETF Ticker	HEALz(USD) CXE
ETF Ticker	HEAL(EUR) ETF Plus
ETF Ticker	DRDR.L(GBP) LSE